Centessa Pharmaceuticals' (CNTA) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Centessa Pharmaceuticals' stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, indicating ongoing negative sentiment among analysts.
• Despite the sell rating from Weiss, multiple firms have issued buy ratings for the stock, with price targets ranging between $28.00 and $40.00.
• The company reported a loss of ($0.38) earnings per share for its last quarter, falling short of the analysts' expectations, and forecasts a -1.6 EPS for the current fiscal year.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Several other research firms have also recently weighed in on CNTA. Truist Financial started coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $30.00 price target on the stock. Guggenheim reaffirmed a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Monday. Chardan Capital reaffirmed a "buy" rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research report on Friday, August 29th. They issued an "outperform" rating and a $40.00 price target on the stock. Finally, Wells Fargo & Company assumed coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They issued an "overweight" rating and a $31.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Centessa Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $32.38.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA traded down $0.82 during midday trading on Wednesday, hitting $22.30. 1,080,546 shares of the stock traded hands, compared to its average volume of 1,195,668. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11. The firm has a market capitalization of $2.99 billion, a P/E ratio of -12.46 and a beta of 1.57. Centessa Pharmaceuticals has a one year low of $9.60 and a one year high of $24.57. The firm has a 50-day moving average of $19.54 and a two-hundred day moving average of $15.46.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). On average, equities analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 8,172 shares of Centessa Pharmaceuticals stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $21.40, for a total transaction of $174,880.80. Following the completion of the transaction, the insider directly owned 197,394 shares of the company's stock, valued at $4,224,231.60. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $15.56, for a total value of $155,600.00. Following the completion of the transaction, the insider directly owned 122,279 shares in the company, valued at $1,902,661.24. This represents a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 205,286 shares of company stock valued at $3,993,345. 7.09% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNTA. GAMMA Investing LLC boosted its stake in Centessa Pharmaceuticals by 1,509.6% in the first quarter. GAMMA Investing LLC now owns 61,762 shares of the company's stock valued at $888,000 after acquiring an additional 57,925 shares during the period. HighMark Wealth Management LLC increased its stake in Centessa Pharmaceuticals by 41.9% in the 1st quarter. HighMark Wealth Management LLC now owns 235,785 shares of the company's stock valued at $3,391,000 after buying an additional 69,650 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Centessa Pharmaceuticals in the 1st quarter valued at about $147,000. Cerity Partners LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $471,000. Finally, Wildcat Capital Management LLC acquired a new stake in shares of Centessa Pharmaceuticals during the first quarter worth $4,053,000. Institutional investors and hedge funds own 82.01% of the company's stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.